151258-20-7

Basic information

• Product Name: 1-(4-BroMoMethyl-benzenesulfonyl)-pyrrolidine, 98+% C11H14BrNO2S, MW: 304.20
• Synonyms: 1-(4-BroMoMethyl-benzenesulfonyl)-pyrrolidine, 98+% C11H14BrNO2S, MW: 304.20;1-[(4-Bromomethylphenyl)sulfonyl]pyrrolidine;4-(Bromomethyl)-1-(1-pyrrolidinylsulfonyl)benzene
• CAS NO: 151258-20-7
• Molecular Formula: C₁₁H₁₄BrNO₂S
• Molecular Weight: 304.20336
• Mol File: 151258-20-7.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 1.547
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-(4-BroMoMethyl-benzenesulfonyl)-pyrrolidine, 98+% C11H14BrNO2S, MW: 304.20(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-BroMoMethyl-benzenesulfonyl)-pyrrolidine, 98+% C11H14BrNO2S, MW: 304.20(151258-20-7)
• EPA Substance Registry System: 1-(4-BroMoMethyl-benzenesulfonyl)-pyrrolidine, 98+% C11H14BrNO2S, MW: 304.20(151258-20-7)

Safety Data

• Hazardous Substances Data: 151258-20-7(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1-(4-BromoMethyl-benzenesulfonyl)-pyrrolidine, 98+% C11H14BrNO2S, MW: 304.20 is utilized as a reagent in organic synthesis, where its unique structure and properties contribute to the creation of new molecules with potential applications across various industries.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1-(4-BromoMethyl-benzenesulfonyl)-pyrrolidine, 98+% C11H14BrNO2S, MW: 304.20 serves as a key component in research and development. Its potential biological activities and the exploration of its medicinal properties make it a significant candidate for the discovery and formulation of new drugs.
Used in Medicinal Chemistry:
1-(4-BromoMethyl-benzenesulfonyl)-pyrrolidine, 98+% C11H14BrNO2S, MW: 304.20 is employed in medicinal chemistry as a potential drug candidate. Its unique structure and properties are leveraged to develop new therapeutic agents, with the aim of addressing unmet medical needs and improving patient outcomes.

Upstream product

• 123-75-1 pyrrolidine 
• 66176-39-4 4-(bromomethyl)benzene-1-sulfonyl chloride 

Downstream Products

• 1219449-65-6 ethyl 2-(2-methyl-3-(4-(pyrrolidin-1-ylsulfonyl)benzyl)-4,5,6,7-tetrahydro-1H-indol-1-yl)acetate 

Relevant articles and documents

Synthesis and initial biological evaluation of new mimics of the LXR-modulator 22(S)-hydroxycholesterol

The generic, synthetic oxysterol 22(S)-hydroxycholesterol (22SHC) has shown antagonistic effects towards liver X receptor (LXR) in vitro and promising effects on plasma triacylglycerol level and body weight-gain in animal studies.1,2 On the contrary, the endogenic LXR agonist 22(R)-hydroxycholesterol (22RHC) and synthetic LXR agonists convincingly have shown agonistic effects on genes involved in lipogenesis, and inhibitory effects on cell proliferation in vitro and in vivo.3 We hypothesized that the carbon side chain containing the hydroxyl group at the 22-position was a pharmacophore affecting these opposite effects on LXR. This prompted us to initiate a rational drug design incorporating the 22-hydroxylated 20-27 cholesterol moiety into cholesterol-mimicking building blocks. The two enantiomers of the 22-hydroxylated 20-27 cholesterol moiety were synthesized with an excellent enantiomeric excess and the stereochemistry are supported by X-ray crystallography. Molecular modelling of the new compounds showed promising LXR selectivity (LXRβ over LXRα) and initial in vitro biological evaluation in human myotubes showed that compound 16b had agonistic effects on the gene expression of SCD1 and increased lipogenesis.